883 A novel CDH17/HER3 bispecific ADC demonstrates superior preclinical efficacy in colorectal cancer

ADCE-T02: A Next-generation Antibody–Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability
Thomas T. Poulsen, Olga Ilina, Jonathan H. Wardman +13
Molecular Cancer Therapeutics25 May 2026Peer-reviewedCC BY-NC-ND 4.0Full text1 citedImmunologyPMC
Efficacy and specific toxicity profiles of GPRC5D- versus BCMA-targeted bispecific antibodies in relapsed/refractory multiple myeloma: a meta-analysis of clinical trials and real-world studies
Jiahao Ji, Xinyu Zhao, Bin Wang +2
Frontiers in immunology16 Oct 2026Peer-reviewedCC BYFull textImmunologyEurope PMC
Superior diagnostic efficacy and cost advantage of FibroTouch over CHI3L1 for liver fibrosis in Chinese patients with chronic liver disease
Zhongbao Zuo, Chunli Yang, Lanlan Hu +9
PLOS One5 Oct 2026Peer-reviewedCC BY 4.0Full textDevelopmental biology Surgery & anaesthesiaPLOS
Molecular subtypes associated with lymph node metastasis in colorectal cancer reveal the tumor-promoting role of GDI1 and the preclinical activity of deslanoside
Jian-hao Zheng, Ruijie Ming, Yibo He +1
Frontiers in Immunology30 Oct 2026Peer-reviewedCC BY 4.0ImmunologyFrontiersCrossref
CD47 blockade augments anti-GD2 driven phagocytosis in vitro but fails to improve in vivo efficacy in immunocompetent, chemoresistant neuroblastoma preclinical models
Courtney Himsworth, Thomas Jackson, Chantelle Bowers +9
PLOS One27 Oct 2026Peer-reviewedCC BY 4.0Full textCell biology ImmunologyPLOSPMC

Cite

BibTeX

@article{shen2026novel,
  title = {{883 A novel CDH17/HER3 bispecific ADC demonstrates superior preclinical efficacy in colorectal cancer}},
  author = {Yuelei Shen and Yiqing Hu and Xueyuan Jiang and Icy Niu and Zeliang Guan},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0883},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0883},
  note = {CC BY},
}

RIS

TY  - JOUR
TI  - 883 A novel CDH17/HER3 bispecific ADC demonstrates superior preclinical efficacy in colorectal cancer
AU  - Yuelei Shen
AU  - Yiqing Hu
AU  - Xueyuan Jiang
AU  - Icy Niu
AU  - Zeliang Guan
PY  - 2026
DA  - 2026/11/08
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0883
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0883
SN  - 2051-1426
ER  -

Related

Cite